Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

REPL

Replimune Group Inc

Apr 10 • 04:00PM ET

4.76

-1.15 -19.46 %

Healthcare • Biotechnology • USA • NASD

Apr 10, 5:35 PMReplimune deems RP1 development non-viable after FDA complete response letter

Peers: MRNA BNTX FATE SGMO KPTI ALVR PGEN ADAP ANIX ENTX

| Held by: XBI VTI IWM VXF FESM IWN IBB VTWO SCHA DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.58	Insider Own	7.27%	Shs Outstand	79.63M	Perf Week	-43.40%
Market Cap	393.05M	Forward P/E	-	EPS next Y	-2.04	Insider Trans	-0.53%	Shs Float	76.57M	Perf Month	-39.75%
Enterprise Value	200.26M	PEG	-	EPS next Q	-0.69	Inst Own	92.96%	Short Float	21.33%	Perf Quarter	-42.16%
Income	-314.85M	P/S	-	EPS this Y	-1.33%	Inst Trans	-3.17%	Short Ratio	9.31	Perf Half Y	4.16%
Sales	0.00M	P/B	1.80	EPS next Y	34.42%	ROA	-67.19%	Short Interest	16.34M	Perf YTD	-51.03%
Book/sh	2.64	P/C	1.46	EPS next 5Y	27.19%	ROE	-90.88%	52W High	13.24 -64.05%	Perf Year	-31.21%
Cash/sh	3.26	P/FCF	-	EPS past 3/5Y	-10.73% -14.85%	ROIC	-111.33%	52W Low	2.68 77.61%	Perf 3Y	-70.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	25.63% 11.42%	Perf 5Y	-84.17%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-13.96%	Oper. Margin	-	ATR (14)	0.83	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.60	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	29.03	Recom	2.14
Dividend Gr. 3/5Y	- -	Current Ratio	5.60	EPS Q/Q	3.16%	SMA20	-33.04%	Beta	0.60	Target Price	13.00
Payout	-	Debt/Eq	0.36	Sales Q/Q	-	SMA50	-36.32%	Rel Volume	1.68	Prev Close	5.91
Employees	479	LT Debt/Eq	0.34	Earnings	Feb 03 BMO	SMA200	-36.77%	Avg Volume	1.76M	Price	4.76
IPO	Jul 20, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.89% 16.66%	Trades		Volume	2,941,489	Change	-19.46%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-26	Downgrade	Piper Sandler	Overweight → Neutral	$4
Nov-03-25	Upgrade	BMO Capital Markets	Underperform → Market Perform	$11
Oct-27-25	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Oct-20-25	Upgrade	Wedbush	Neutral → Outperform	$18
Oct-20-25	Upgrade	Piper Sandler	Neutral → Overweight	$13
Oct-20-25	Upgrade	Leerink Partners	Market Perform → Outperform	$13
Oct-20-25	Upgrade	JP Morgan	Underweight → Neutral
Sep-19-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jul-23-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-23-25	Downgrade	BMO Capital Markets	Outperform → Underperform	$2
Jul-23-25	Downgrade	Barclays	Overweight → Equal Weight	$3
Jul-22-25	Downgrade	Wedbush	Outperform → Neutral	$4
Jul-22-25	Downgrade	Piper Sandler	Overweight → Neutral	$3
Jul-22-25	Downgrade	Leerink Partners	Outperform → Market Perform	$3
Jul-22-25	Downgrade	JP Morgan	Overweight → Neutral	$9
Jun-20-25	Initiated	Cantor Fitzgerald	Overweight
Aug-28-24	Initiated	ROTH MKM	Buy	$17
Apr-17-23	Resumed	Piper Sandler	Overweight	$44
Nov-19-21	Initiated	Piper Sandler	Overweight	$52

Show Previous Ratings

Apr-10-26 05:02PM	Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma (GlobeNewswire) -19.46%
12:17PM	Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second Time (Barrons.com)
Mar-10-26 11:31AM	JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer (Zacks)
11:26AM	XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study (Zacks)
Mar-09-26 01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal) +6.94%
08:27AM	Loading…
Mar-06-26 08:27AM	Mirum Completes Enrollment & Screening in Liver Disease Studies (Zacks) +14.63%
Mar-05-26 12:43PM	Bayer Advances Roundup Settlement With Missouri Court Approval (Zacks)
Mar-04-26 10:36AM	ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M (Zacks)
Mar-03-26 09:55AM	Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? (Zacks)
05:30AM	MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines (The Wall Street Journal)
Mar-02-26 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire) -6.41%
Feb-12-26 09:55AM	Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know (Zacks)
Feb-03-26 08:00AM	Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +5.81%
Dec-31-25 02:42PM	Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months (Zacks)
Dec-18-25 08:00AM	Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
04:45PM	Loading…
Nov-07-25 04:45PM	Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) (GlobeNewswire)
Nov-06-25 08:00AM	Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-22-25 05:47PM	The Best AI for Picking Stocks, Ranked by Performance (MarketBeat)
Oct-20-25 04:10PM	Why Replimune Stock Was Soaring Today (Motley Fool) +98.78% -9.45%
07:00AM	Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma (GlobeNewswire)
Oct-19-25 08:00AM	Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 (GlobeNewswire)
Sep-24-25 11:06AM	REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug (Zacks)
Sep-22-25 05:35AM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (PR Newswire)
Sep-19-25 04:08PM	Why Replimune Stock Was Tumbling Again Today (Motley Fool) -6.79%
10:12AM	Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment 'Uncertain' (Insider Monkey)
09:39AM	Intel downgraded, Tesla upgraded: Wall Street's top analyst calls (The Fly)
Sep-18-25 06:59PM	Why Replimune Stock Plummeted by Almost 40% Today (Motley Fool) -39.40%
09:15AM	Replimune Provides Update Following Type A Meeting with FDA (GlobeNewswire)
05:48AM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (PR Newswire)
Sep-12-25 04:42PM	Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025 - Contact Levi & Korsinsky (Newsfile)
12:56PM	Loading…
Sep-04-25 12:56PM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (Business Wire)
09:30AM	Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman (PR Newswire)
Sep-03-25 04:18PM	Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman (PR Newswire)
Sep-02-25 08:00AM	Replimune Announces Type A Meeting Scheduled with FDA (GlobeNewswire) +9.26%
Aug-28-25 08:12AM	Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman (Newsfile)
Aug-26-25 08:46AM	Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL (PR Newswire)
Aug-25-25 09:31AM	Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 (Newsfile)
Aug-20-25 05:04PM	Investors in Replimune Group, Inc. (REPL): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile) +6.67%
Aug-14-25 04:19PM	Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 (Newsfile) +5.11%
Aug-13-25 03:40PM	Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025 - Contact Levi & Korsinsky (Newsfile)
Aug-12-25 09:00AM	Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REPL (PR Newswire) +5.21%
Aug-11-25 11:01AM	Controversial FDA regulator back 12 days after resigning (Quartz) -5.67%
Aug-07-25 08:00AM	Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 08:45AM	Replimune Group, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL (PR Newswire) +10.68%
Aug-04-25 09:52AM	Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 (Newsfile) -24.87%
Jul-30-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +101.33%
Jul-23-25 03:46PM	REPL STOCK LOSS: BFA Law Notifies Replimune Group, Inc. Investors to Contact the Firm after Stock Drops 75% on FDA Response Letter (Newsfile) +18.89%
Jul-22-25 04:07PM	Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock (Investor's Business Daily) -77.24%
11:05AM	Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment (Barrons.com)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
10:05AM	FDA Rejects Replimunes Skin Cancer Treatment, Shares Sink (Bloomberg)
07:00AM	Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma (GlobeNewswire)
Jul-11-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.46%
Jun-01-25 10:00AM	Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-29-25 08:00AM	Replimune to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) +11.15%
May-23-25 03:03AM	Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
12:02AM	Q4 2025 Replimune Group Inc Earnings Call (Thomson Reuters StreetEvents)
May-22-25 07:00AM	Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-16-25 08:00AM	Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day (GlobeNewswire) +8.58%
May-09-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-25 03:26PM	Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma (Seeking Alpha)
Apr-27-25 09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
Apr-11-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.21%
Mar-07-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-25 08:00AM	Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.32%
Feb-07-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.88%
Jan-23-25 07:06AM	Replimune price target raised to $21 from $17 at H.C. Wainwright (TipRanks) +5.61%
Jan-21-25 01:01PM	Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy (GuruFocus.com) +16.86%
08:00AM	Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma (GlobeNewswire)
Jan-10-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-25 08:00AM	Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials (GlobeNewswire)
Dec-23-24 08:00AM	Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-25-24 11:55PM	Replimune Announces Pricing of Upsized Public Offering (GlobeNewswire) -11.19% +8.45%
07:09AM	Replimune Announces Proposed Public Offering (GlobeNewswire)
Nov-22-24 04:00PM	S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results (Benzinga) +35.11%
05:48AM	Replimune's stock surges 19% after-hours on FDA BLA submission (Investing.com)
Nov-21-24 04:05PM	Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway (GlobeNewswire)
Nov-12-24 08:00AM	Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-24 01:00PM	Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) (GlobeNewswire)
Nov-08-24 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-24 09:15AM	Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Oct-09-24 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
Oct-07-24 09:11PM	Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings (GuruFocus.com)
Oct-01-24 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.58%
Sep-15-24 09:45AM	Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-09-24 08:00AM	Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024 (GlobeNewswire)
Sep-05-24 08:00AM	Stockholders Vote to Elect Madhavan Balachandran to Board of Directors (GlobeNewswire)
Aug-22-24 08:00AM	Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Aug-14-24 04:33PM	Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy (Pharmaceutical Technology)
Aug-13-24 08:00AM	Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma (GlobeNewswire)
Aug-08-24 08:00AM	Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-30-24 04:01PM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Jun-13-24 08:30AM	Replimune Announces $100 Million Private Placement Financing (GlobeNewswire) +7.26%
Jun-07-24 09:03AM	Replimune (REPL) Gains on Positive Data From Melanoma Study (Zacks) +11.11%
08:00AM	Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-06-24 12:16PM	Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? (Benzinga) +27.88%
07:00AM	Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma (GlobeNewswire)
Jun-03-24 08:00AM	Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-23-24 05:00PM	Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.77%

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sarchi Christopher	Chief Commercial Officer	Apr 02 '26	Sale	8.01	6,500	52,065	151,588	Apr 06 04:30 PM
Christopher Sarchi	Officer	Apr 02 '26	Proposed Sale	7.70	18,500	142,450		Apr 02 04:15 PM
Dhingra Kapil	Director	Dec 09 '25	Option Exercise	1.75	3,169	5,546	3,169	Dec 11 04:30 PM
Dhingra Kapil	Director	Dec 09 '25	Sale	10.40	3,169	32,958	0	Dec 11 04:30 PM
Kapil Dhingra	Director	Dec 09 '25	Proposed Sale	10.38	3,164	32,842		Dec 09 04:00 PM
Patel Sushil	Chief Executive Officer	Dec 02 '25	Sale	11.13	10,000	111,300	333,576	Dec 04 04:30 PM
Sushil Patel	Chief Strategy Officer	Dec 02 '25	Proposed Sale	11.13	10,000	111,303		Dec 02 04:11 PM
Sarchi Christopher	Chief Commercial Officer	Nov 17 '25	Sale	9.10	5,208	47,393	123,088	Nov 19 04:31 PM
Xynos Konstantinos	Chief Medical Officer	Nov 17 '25	Sale	9.10	7,248	65,957	139,685	Nov 19 04:30 PM
Hill Emily Luisa	Chief Financial Officer	Aug 15 '25	Sale	5.37	9,154	49,157	134,368	Aug 19 08:30 PM
Astley-Sparke Philip	Director	May 20 '25	Sale	8.06	32,279	260,169	1,405,071	May 22 09:47 PM
Xynos Konstantinos	Chief Medical Officer	May 20 '25	Sale	8.06	7,952	64,093	146,933	May 22 09:46 PM
Schwendenman Andrew	Chief Accounting Officer	May 20 '25	Sale	8.05	3,287	26,460	68,284	May 22 09:45 PM
Patel Sushil	Chief Executive Officer	May 20 '25	Sale	8.06	25,105	202,346	343,576	May 22 09:44 PM
Hill Emily Luisa	Chief Financial Officer	May 20 '25	Sale	8.05	2,535	20,407	143,522	May 22 09:44 PM
Sarchi Christopher	Chief Commercial Officer	May 20 '25	Sale	8.05	3,749	30,179	128,296	May 22 09:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REPL

Replimune Group Inc

Upgrade your Finviz experience